Related Articles
Efficacy of tyrosine kinase inhibitors in non‑small‑cell lung cancer patients undergoing dose reduction and those with a low body surface area
Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor‑mutated non‑small‑cell lung cancer
Phase I trial of nedaplatin and S‑1 in patients with advanced squamous cell lung cancer
Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients
EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan